--- canonical_name: UV Blood Irradiation alternate_names: Ultraviolet Blood Irradiation, UBI, UVBI, Ultraviolet Blood Irradiation Therapy, Hemo-Irradiation, Knott Technique, Photoluminescence Therapy canonical_topic: UV Blood Irradiation for Health & Longevity short_topic_lc: uv_blood_irradiation creation_date: 2026-0811-0535 creator_ai_fullname: Grok 4 --- # UV Blood Irradiation for Health & Longevity

Evidence Review created on 08/11/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4 **Also known as:** Ultraviolet Blood Irradiation, UBI, UVBI, Ultraviolet Blood Irradiation Therapy, Hemo-Irradiation, Knott Technique, Photoluminescence Therapy ## Motivation Ultraviolet blood irradiation (also called UBI or UVBI) is a procedure in which a small portion of a person's blood is drawn, passed through a chamber and exposed to controlled ultraviolet light, then returned to the circulation. Interest among health- and longevity-oriented adults stems from claims that this brief light exposure can support immune balance, help the body handle hard-to-treat infections, and reduce systemic inflammation—areas central to many longevity strategies. The method has a nearly century-long clinical lineage. It was used in the United States in the 1930s–1950s for serious infections before antibiotics became standard, later continued in parts of Eastern Europe and Russia, and has reappeared in integrative and longevity clinics, sometimes combined with oxygen or ozone. A related hospital procedure that uses light-sensitizing drugs on white blood cells is approved for a rare skin lymphoma; ordinary UBI for general wellness is not. This review examines the evidence for and against ultraviolet blood irradiation as a health and longevity intervention: what the historical and modern clinical literature shows, proposed mechanisms, expected benefits and risks, protocol patterns, and practical considerations for risk-aware adults who evaluate such therapies carefully. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level overviews and expert commentary that introduce ultraviolet blood irradiation, its history, proposed mechanisms, and contested status. * [Ultraviolet Irradiation of Blood: "The Cure That Time Forgot"?](https://pubmed.ncbi.nlm.nih.gov/29124710/) - Hamblin, 2017 Photomedicine researcher's widely cited chapter summarizing 1940s–1950s U.S. clinical use, immune and antimicrobial mechanisms, and why the method is distinct from extracorporeal photopheresis. * [Use of Ultraviolet Blood Irradiation Against Viral Infections](https://pubmed.ncbi.nlm.nih.gov/33026601/) - Boretti et al., 2021 Review focused on antiviral and immune-modulating actions in the context of emerging viral threats, with comparison to more complex photopheresis methods. * [Shedding Light on UV Blood Irradiation](https://www.mcgill.ca/oss/article/medical-critical-thinking-technology/shedding-light-uv-blood-irradiation) - Jonathan Jarry Critical public-science analysis separating FDA-approved extracorporeal photopheresis from clinic-marketed UBI and flagging evidence and cost gaps for wellness claims. * [Ultraviolet Blood Irradiation: New Hope for Chronic COVID](https://riordanclinic.org/2023/11/ultraviolet-blood-irradiation-new-hope-for-chronic-covid/) - Thomas Levy, MD, JD Integrative clinician overview of historical infection series and modern clinic use, including long-COVID interest; represents the proponent clinical perspective. Fewer than five high-quality overview sources met inclusion rules after excluding a second Hamblin-coauthored narrative (Wu et al., 2016) for one-item-per-expert; none of the listed priority platforms published dedicated UBI content as of the search date above. ## Grokipedia * [Blood irradiation therapy](https://grokipedia.com/page/Blood_irradiation_therapy) Overview of extracorporeal UV and laser blood irradiation, history from Knott's work, proposed mechanisms, clinical applications, safety notes, and regulatory status. ## Examine No Examine.com article was found for UV Blood Irradiation. ## ConsumerLab No ConsumerLab article was found for UV Blood Irradiation. ## Systematic Reviews No systematic reviews or meta-analyses for UV Blood Irradiation were found on PubMed as of August 11, 2026. ## Mechanism of Action Ultraviolet blood irradiation exposes a small extracorporeal blood volume—classically about 5–7% of estimated circulating volume, or roughly 3.5 mL per kilogram—to ultraviolet light, most often UVC (short-wavelength ultraviolet C light) near 253.7 nm from a mercury-quartz source, then returns it to the vein. Pathogens absorb UV energy efficiently; low-to-moderate doses form thymine dimers in microbial DNA and can inactivate bacteria and viruses in the treated aliquot. That direct kill cannot fully explain clinical reports, because only a minority of blood is irradiated. Host effects appear to dominate. Reviews ([Hamblin, 2017](https://pubmed.ncbi.nlm.nih.gov/29124710/)) summarize enhanced phagocytic (particle-engulfing) activity of neutrophils and dendritic cells, altered lymphocyte behavior, shifts in cytokines (signaling proteins that coordinate immune responses), oxidation of blood lipids, and red-cell membrane changes that may improve microcirculation. UV-modified plasma proteins such as albumin can acquire altered antioxidant behavior in laboratory models. These signals share ground with ozone and other controlled oxidative therapies: brief oxidative stress may prime immune surveillance without sterilizing the whole bloodstream. UBI is distinct from extracorporeal photopheresis (ECP), in which white cells are separated, exposed to UVA (long-wavelength ultraviolet A light) with a psoralen (light-sensitizing) drug, and reinfused mainly for immunosuppressive goals (e.g., cutaneous T-cell lymphoma). Standard UBI uses whole blood without a photosensitizing drug and is described as more immunostimulatory than ECP. Excess UV may blunt benefit or raise host-cell stress, so devices calibrate exposure time and path length in a quartz cuvette. ## Historical Context & Evolution Emmett K. Knott developed a practical hemo-irradiator in the late 1920s; early clinical use for sepsis (severe bloodstream infection) appeared around 1928. Through the 1940s and early 1950s, U.S. surgeons and physicians published series in the *American Journal of Surgery* describing Knott-technique UBI for septicemia (blood poisoning), pneumonia, peritonitis (abdominal lining infection), thrombophlebitis (vein inflammation with clot), biliary infection, asthma, and viral hepatitis. Reported outcomes in pre-antibiotic and early-antibiotic eras were often dramatic by modern standards, though designs were uncontrolled case series without today's randomization, blinding, or standardized endpoints. As penicillin and later antibiotics scaled, UBI use in Western mainstream practice declined sharply—later labeled “the cure that time forgot.” Research and clinical use continued more actively in the Soviet Union, Russia, and other Eastern European settings, including coronary and inflammatory work. Western interest later resurfaced among integrative clinics, sometimes combining UV with medical oxygen or ozone. A related technology—extracorporeal photopheresis with psoralens—received U.S. regulatory approval for cutaneous T-cell lymphoma and is used off-label for graft-versus-host disease; that approval is not an approval of classic Knott-style UBI for infections or wellness. Modern reappraisal argues that multi-drug-resistant infections and limited antiviral options justify rigorous re-study. Critical science communicators note that historical success rates and clinic marketing often outrun controlled evidence for non-ECP indications. The record documents real clinical use and plausible biological effects, not a settled modern efficacy package for longevity or general health. ## Expected Benefits ### Low 🟩 #### Reduced hepatitis C viral load (historical trial context) In a small FDA device Phase II trial ([Kuenstner et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26092299/)), nine hepatitis C virus (HCV) patients received fifteen UVBI sessions over ~22 weeks. Mean viral load fell modestly (~21–45% by timepoint); a device-firm (AVIcure) author interest applies. Not a longevity study. **Magnitude:** Mean HCV viral load reduction of approximately 21–45% across timepoints in n = 9 (Kuenstner et al., 2015); not competitive with modern antiviral cure rates. #### Support in acute bacterial and viral infections (historical series) 1940s–1950s U.S. Knott-technique series reported rapid improvement in septicemia, pneumonia, peritonitis, and related infections, often with recovery rates extraordinary by modern standards. Reports were uncontrolled and predate contemporary intensive care. They remain the largest human outcome narrative for classic UBI but cannot alone establish efficacy today. **Magnitude:** Not quantified in available studies. #### Immune modulation (phagocyte activation and cytokine shifts) Modern reviews ([Hamblin, 2017](https://pubmed.ncbi.nlm.nih.gov/29124710/); [Boretti et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33026601/)) report that UV-treated blood can increase phagocytic capacity, alter lymphocyte activity, and change cytokine patterns. Human translation for longevity-relevant endpoints lacks large randomized trials. Effects remain incompletely characterized in wellness populations. **Magnitude:** Not quantified in available studies. #### Anti-inflammatory and symptom relief in chronic inflammatory conditions Historical and clinic-level reports describe benefit in asthma, arthritis, and psoriasis (including incidental psoriasis improvement in the HCV trial). Evidence consists of old case series, small observations, and uncontrolled integrative practice—not multi-center randomized trials with validated inflammatory scores in longevity cohorts. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Longevity, general wellness, and “immune optimization” in healthy adults Longevity clinics market UBI for vitality and immune readiness in people without acute infection. No controlled trials show effects on lifespan, healthspan biomarkers, or morbidity in healthy adults; claims rest on mechanism and practitioner experience. #### Adjunct for multidrug-resistant infections or emerging viruses Reviews ([Hamblin, 2017](https://pubmed.ncbi.nlm.nih.gov/29124710/)) urge study where antibiotics fail, noting UV resistance is not reported like drug resistance. Human efficacy data in defined resistant-infection populations remain sparse; the case is mechanistic rather than outcome-proven. #### Long COVID and post-viral symptom complexes Integrative clinics report UBI (sometimes with oxygen or ozone) for post-viral symptoms. Controlled evidence for standard UBI-only protocols in long COVID is essentially absent; support is anecdotal. ## Benefit-Modifying Factors * **Active infection burden:** Historical rationale and modern reviews ([Hamblin, 2017](https://pubmed.ncbi.nlm.nih.gov/29124710/)) emphasize greatest clinical signal when infection or immune challenge is present; benefit in asymptomatic healthy adults is unproven. * **UV dose and blood volume treated:** Tradition holds that roughly 5–7% of blood volume (about 3.5 mL/kg) is optimal; under- or over-exposure may reduce benefit or increase oxidative stress on host cells. * **Device wavelength and cuvette design:** Line-spectrum mercury UVC versus full-spectrum flash xenon sources can differ in effective dose to plasma proteins; protocol translation across devices is imperfect. * **Concurrent oxidative therapies:** Many clinics combine UBI with ozone or oxygen; attributed benefits may reflect the combination rather than UV alone. * **Baseline inflammatory or autoimmune activity:** Individuals with active inflammatory disease may show larger subjective or laboratory shifts than low-inflammation longevity seekers. * **Age and immune senescence:** Older adults with immunosenescence (age-related decline in immune function) are a theoretical target population for immune-modulating therapies, but age-stratified controlled UBI data are lacking. * **Sex-based differences:** No robust sex-specific efficacy data for classic UBI were identified in the available literature. ## Potential Risks & Side Effects ### Medium 🟥 🟥 #### Procedure-related local effects (bruising, phlebitis, puncture-site issues) UBI requires venous access and extracorporeal blood handling. As with any intravenous (IV) procedure, local bruising, discomfort, superficial phlebitis (vein inflammation), and rare local infection can occur. Clinic reports list injection-site pain and bruising among the most common complaints. Sterile technique and trained staff reduce—but do not eliminate—these risks. **Magnitude:** Not quantified in available studies. #### Transient flu-like symptoms and post-treatment fatigue Patients commonly report short-lived fatigue, mild fever, chills, myalgia (muscle pain), or “die-off”-type symptom flares in the hours to days after sessions. These are interpreted by practitioners as immune activation or pathogen fragment clearance (sometimes labeled a Herxheimer-like reaction—a temporary symptom flare after antimicrobial or immune activation). Symptoms usually resolve within one to two days in clinic accounts. **Magnitude:** Not quantified in available studies. ### Low 🟥 #### Systemic reactions in treatment series (rigor, hypotension, other) A 2,380-session series reported technical issues in about 1.3% and uncommon events (rigor [shaking chills], hypotension, nasal bleeding, hypoglycemia, bronchospasm [airway narrowing], urticaria [hives]). Autonomic instability, volume depletion, or brittle diabetes may raise blood-pressure or blood-sugar shift risk. Authors advised post-session carbohydrates and monitoring; serious events appear rare. **Magnitude:** Serious clinical complications were rare in a 2,380-session series ([Marochkov et al., 1990](https://pubmed.ncbi.nlm.nih.gov/2077972/)); technical issues ≈1.3%. ### Speculative 🟨 #### Excess oxidative modification of plasma proteins at high UV dose Lab work shows dose-dependent UV oxidation of albumin with altered transport and antioxidant behavior. Whether repeated clinic doses impair protein function in vivo is not established. #### Theoretical DNA stress in host cells UV damages nucleic acids; host repair systems are cited as protective at therapeutic doses. Long-term cancer risk from repeated extracorporeal UVC on a small blood fraction has not been shown and remains theoretical. ## Risk-Modifying Factors * **Venous access quality and sterile technique:** Poor technique raises phlebitis and infection risk; closed sterile systems and trained operators lower it. * **UV dose relative to blood volume:** Exceeding traditional 5–7% volume or prolonging exposure may increase host-cell and protein oxidative stress. * **Photosensitizing medications:** Drugs that heighten UV sensitivity (e.g., certain antibiotics, diuretics, retinoids) warrant caution even though exposure is extracorporeal and brief. * **Baseline hemodynamic status:** Dehydration, orthostatic hypotension (blood pressure drop on standing), or antihypertensive polypharmacy may increase post-session lightheadedness risk. * **Glucose status:** Prior hypoglycemia events and fasting before treatment may raise risk of session-related low blood sugar. * **Bleeding tendency:** Anticoagulants or platelet disorders increase bruising and hematoma risk at venipuncture sites. * **Age-related frailty:** Older adults may tolerate volume shifts and flu-like flares less well; monitoring intensity should match clinical status. * **Sex-based differences:** No consistent sex-specific risk profile for UBI was identified in the reviewed literature. ## Key Interactions & Contraindications * **Photosensitizing drugs (tetracyclines, fluoroquinolones, sulfonamides, amiodarone, thiazides, retinoids):** Caution — theoretical enhancement of UV cellular stress in the treated aliquot; coordinate timing and medical review. * **Anticoagulants and antiplatelet agents (warfarin, DOACs [direct oral anticoagulants], aspirin, clopidogrel):** Monitor — increased bruising and puncture-site bleeding; apply extended pressure and avoid unnecessary trauma. * **Photosensitizing or immune-active supplements (e.g., St. John's wort, high-dose photosensitizing botanicals):** Caution — theoretical additive light sensitivity in the treated blood aliquot; review the full supplement list before courses. * **Antihypertensives and volume-depleting agents:** Monitor — additive risk of post-session hypotension or lightheadedness; ensure hydration. * **Glucose-lowering drugs (insulin, sulfonylureas):** Monitor — rare hypoglycemia reports after sessions; take food as advised by the treating team. * **Concurrent ozone or high-dose oxidative IV therapies:** Caution — additive oxidative load; combination protocols are common in clinics but lack standardized safety datasets separating UV from ozone effects. * **Immunosuppressants:** Caution — UBI is framed as immune-modulating; theoretical interaction with intentional immunosuppression warrants specialist input. **Populations who should avoid UV Blood Irradiation:** * Uncontrolled porphyria (disorder of heme synthesis causing light sensitivity) or severe photosensitivity disorders (pending specialist clearance) * Pregnancy (precautionary absence of safety data) * Active untreated bacteremia (bacteria in the bloodstream) with unstable sepsis when standard critical care is the priority setting * Severe anemia or inability to tolerate extracorporeal blood draw of the planned volume * Known allergy to materials in the tubing or cuvette set * Inability to obtain safe venous access ## Risk Mitigation Strategies * **Qualified supervised setting:** Use physician-directed clinics with sterile closed systems and trained staff to reduce infection and dosing errors. * **Conservative dose and volume:** Stay near classical 3.5 mL/kg or 5–7% blood volume and validated device settings to limit host oxidative overexposure. * **Hydration and nutrition:** Eat and hydrate before sessions; have carbohydrates available afterward to reduce hypoglycemia and lightheadedness risk. * **Venipuncture care:** Apply prolonged pressure, avoid intramuscular (IM) injections for ~1–2 hours post-session if advised, and inspect sites for hematoma. * **Medication review:** Pause or time photosensitizers and adjust bleeding-risk drugs only under the prescribing clinician's plan to reduce UV stress and puncture-site bleeding. * **Observation window:** Remain monitored for early hypotension, rigor, or allergic signs after reinfusion, especially on first sessions. * **Symptom tracking:** Log fatigue and flu-like flares; reduce frequency if recovery consistently exceeds 48 hours. * **Do not replace standard care:** Keep UBI as investigational adjunct; treat emergencies and guideline-directed infections with established therapies first. ## Therapeutic Protocol * **Classic Knott-style volume:** About 3.5 mL/kg or 5–7% of estimated blood volume (often 60–200 mL in adults) is withdrawn, anticoagulated, passed through a UV chamber, and reinfused. * **Wavelength:** Historical devices used mercury-quartz UVC peaking near 253.7 nm; modern clinic units may use UVA/UVC combinations or flash xenon sources—confirm device specification. * **Session frequency:** Common integrative patterns are 1–3 sessions per week for several weeks, then as-needed maintenance; the FDA HCV trial used 15 treatments over ~22 weeks. * **Duration of session:** Extracorporeal exposure per unit volume is brief (order of seconds in chamber transit in classical descriptions); total appointment time is usually under an hour including setup. * **Combined protocols:** Many longevity and integrative clinics add medical ozone and/or 100% oxygen (HOT-style hematogenous oxidation therapy) and sometimes high-dose intravenous vitamin C after reinfusion—effects cannot be attributed to UV alone. * **Time of day:** No established circadian optimum; morning sessions may ease monitoring of same-day fatigue. * **Half-life / split dosing:** Not a circulating drug; no pharmacokinetic half-life. Effects are procedural; splitting daily blood volume is not standard. * **Genetics, sex, age, biomarkers:** No validated pharmacogenetic dose algorithms; older or frail patients may start with fewer sessions; inflammatory markers and clinical status guide continuation more than a fixed lab panel. * **Competing approaches:** Hospital ECP (psoralen + UVA on separated leukocytes) is a different procedure with different indications; intravascular laser blood irradiation (ILBI) uses red/near-infrared laser, not UVC, and is a separate modality popular in some European and Asian practices. ## Discontinuation & Cycling * **Course length:** Typically short-term or intermittent courses rather than lifelong daily therapy; infection-focused series were finite; wellness use is often cyclic. * **Withdrawal effects:** No classic drug-withdrawal syndrome is described; stopping ends procedural exposure without taper of a pharmacologic agent. * **Tapering:** Not required pharmacologically; frequency can be reduced as symptoms or goals change under clinician guidance. * **Cycling:** Clinics often cycle blocks of sessions with rest intervals to reassess need and avoid unnecessary repeated venipuncture. * **Re-treatment:** May be repeated if symptoms recur (e.g., clinic protocols for fluctuating post-viral markers), subject to ongoing risk–benefit review. ## Sourcing and Quality * **Medical device status:** UBI is delivered via specialized irradiators, not a dietary supplement; consumer “buy and DIY” use is inappropriate and unsafe. * **Device pedigree:** Prefer clinics using closed sterile disposable kits and devices with clear wavelength, dose documentation, and maintenance logs; modified Knott-type systems differ from ECP machines. * **Operator training:** Outcomes and safety depend heavily on sterile technique and protocol fidelity; ask about training, emergency preparedness, and physician oversight. * **Regulatory clarity:** Classic UBI for infections or wellness is not an FDA-approved indication in the United States; ECP for cutaneous T-cell lymphoma is a different approved pathway—do not conflate marketing language. * **Clinic financial incentives:** Providers who sell UBI packages have revenue tied to utilization; independent medical judgment should separate fee structure from evidence quality. * **Combination transparency:** If ozone, oxygen, or IV nutrients are bundled, request the exact protocol so effects and costs can be evaluated component-wise. ## Practical Considerations * **Time to effect:** Historical infection series sometimes described improvement within 24–48 hours; wellness and chronic inflammatory goals, when claimed, are often assessed over multiple sessions across weeks. * **Common pitfalls:** Equating clinic testimonials with randomized controlled trial (RCT) evidence; confusing UBI with FDA-approved ECP; assuming all UV devices deliver equivalent dose; using UBI as a substitute for antibiotics or antivirals when those are indicated. * **Regulatory status:** Investigational/complementary for most marketed uses in the U.S.; insurance coverage is typically absent for wellness indications. * **Cost and access:** Out-of-pocket fees commonly cited in public analyses on the order of roughly $100–$350 per session with multi-session packages; geographic access is limited to specialized clinics. * **Opportunity cost:** Money and time spent on UBI may displace higher-evidence longevity fundamentals (sleep, resistance training, metabolic health, proven vaccines and medications). ## Interaction with Foundational Habits * **Sleep:** Direction largely none to indirect. Transient post-session fatigue may temporarily alter sleep need; no evidence UBI systematically improves or disrupts sleep architecture. Practical note: schedule demanding cognitive work away from first-session recovery days. * **Nutrition:** Indirect potentiating for safety. Adequate pre-session food and carbohydrate availability reduce hypoglycemia risk reported in older safety literature. No specific diet is required for UV efficacy; maintain protein and micronutrient sufficiency for immune competence generally. * **Exercise:** Indirect. Same-day intense training after a first session may compound fatigue; many people resume normal activity quickly. No data show blunting of hypertrophy or cardio adaptations from standard UBI courses. * **Stress management:** Indirect. Procedure anxiety and flu-like flares can transiently raise perceived stress; calm environment and clear expectations mitigate. No controlled evidence that UBI lowers cortisol or improves stress resilience as a primary endpoint. ## Monitoring Protocol & Defining Success Baseline assessment before a UBI course should establish clinical goals (e.g., infection clearance metrics versus subjective energy), venous access feasibility, full medication and supplement list (photosensitizers, anticoagulants, antihypertensives, glucose-lowering agents), and relevant disease-specific labs or imaging already in use for the indication. Record resting blood pressure, orthostatic vitals if lightheadedness is a concern, and a brief symptom score so later change is measurable. Ongoing monitoring pairs safety observation after each session with periodic labs matched to the indication—not a universal “longevity panel” unique to UBI. Cadence commonly used in practice: clinical check at each visit; laboratory reassessment at roughly 4 weeks and at course end, then as indicated every 3–6 months if courses repeat. Qualitative markers (energy, recovery, symptom scores) are tracked weekly during active treatment. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | CBC with differential | Individual baseline; investigate unexplained cytopenias (low blood-cell counts) | Tracks infection response and procedural blood loss tolerance | Complete blood count; fasting not required; compare to pre-course baseline | | CRP (hs-CRP) | Often targeted <1.0 mg/L in optimization contexts | General inflammation trend | C-reactive protein (high-sensitivity); conventional “normal” can be higher; pair with clinical status | | CMP (glucose, electrolytes, renal, hepatic enzymes) | Glucose mid-normal fasting; eGFR stable for age; liver enzymes near personal baseline | Safety around sessions; liver context if viral hepatitis history | Comprehensive metabolic panel; eGFR = estimated kidney filtration rate; fasting glucose if metabolic disease | | Indication-specific viral load or culture data | Per disease guidelines | Objective infection endpoint when relevant | E.g., HCV RNA only if treating hepatitis C under research/clinical protocols | | Blood pressure and orthostatic vitals | Individual optimal; no symptomatic drop | Detect hypotension risk | Measure pre- and post-session early in a course | Success is defined against the pre-stated goal: objective infection or inflammatory markers when those were the target; otherwise, pre-agreed symptom scales and function. Absence of progressive adverse events and preserved venous access are minimum safety success criteria. Qualitative markers: * Post-session recovery time (target resolution of flu-like symptoms within 24–48 hours) * Energy and exercise tolerance across the treatment week * Sleep quality and daytime alertness * Disease-specific symptom scores (e.g., joint pain, respiratory symptoms) when applicable ## Emerging Research * **Antibiotic resistance rationale:** [Hamblin](https://pubmed.ncbi.nlm.nih.gov/29124710/) and [Wu et al.](https://pubmed.ncbi.nlm.nih.gov/26894849/) argue multi-drug-resistant bacteria remain UV-susceptible and that UBI merits modern RCTs as immune-modulating infection adjuncts. * **Antiviral reappraisal:** [Boretti et al.](https://pubmed.ncbi.nlm.nih.gov/33026601/) review UBI mechanisms against viral pathogens and call for device-level research on viruses with limited drug options. * **Dose optimization of light sources:** [Sozarukova et al.](https://pubmed.ncbi.nlm.nih.gov/37375200/) compare line-spectrum mercury versus full-spectrum flash xenon effects on plasma proteins, informing safer individual dose selection. * **FDA-path device trials:** The [Kuenstner et al.](https://pubmed.ncbi.nlm.nih.gov/26092299/) HCV Investigational Device Exemption (IDE) study (and related open reports) illustrates a regulatory-device pathway; replication in other infections would strengthen or weaken clinical claims. * **Registry-level clinic data:** Integrative centers publish observational long-COVID and chronic-infection experience; controlled trials with standardized UBI-only arms (without ozone co-intervention) would clarify attribution. * **ClinicalTrials.gov landscape:** Dedicated interventional NCT registrations for classic Knott-style UBI wellness or infection indications are sparse as of this review; most UV/blood trial hits concern photopheresis, pathogen reduction for transfusion products, or unrelated “UBI” acronyms. Future registered RCTs would materially change confidence. ## Conclusion Ultraviolet blood irradiation is a nearly century-old procedure in which a small fraction of blood is drawn, exposed to ultraviolet light outside the body, and returned to the vein. Health- and longevity-oriented adults encounter it in integrative clinics as a candidate for immune support, infection resilience, and inflammation control. Historical reports from the pre-antibiotic and early-antibiotic eras describe extensive use with dramatic uncontrolled outcomes; modern narrative reviews outline plausible immune, antimicrobial, and small-vessel blood-flow mechanisms and distinguish the method from the related hospital procedure that treats separated white blood cells with a light-sensitizing drug plus UV light. Controlled contemporary evidence is thin. A small device trial in hepatitis C—with device-firm (AVIcure) authorship interest—showed modest virus reductions in blood and some laboratory shifts with acceptable short-term safety, but those results sit far below current antiviral standards and do not establish a longevity benefit. Most other human support remains uncontrolled historical series, laboratory work, and clinic experience—often from parties who also deliver and charge for the service. Common risks are local needle-site issues and short-lived flu-like fatigue; serious events appear uncommon in large older session series when dose and technique are held. For a risk-aware optimization audience, ultraviolet blood irradiation is best understood as an experimental procedure with rich history and incomplete modern proof—not as a validated lifespan or healthy-years-of-life therapy. Evidence quality is generally low outside narrow historical and small-trial contexts; wellness claims remain speculative relative to foundational lifestyle. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**